Production of an O-desmethylated product, a major human metabolite, of rabeprazole sulfide by bacterial P450 enzymes
Enzyme and Microbial Technology · 2023
DOI: 10.1016/j.enzmictec.2023.110328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Enzyme and Microbial Technology, 2023. Verfasst von Ngoc Tan Cao und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Sciences and Technology, Chonnam National University, 77 Yongbongro, Gwangju 61186, Republic of Korea. Hauptthemen laut MEDLINE: Cytochrome P-450 Enzyme System, Proton Pump Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Research Foundation of Korea, Ministry of Science, ICT and Future Planning.
Abstract (Originalsprache)
Rabeprazole is a common type of proton pump inhibitor (PPI) used to treat various peptic disorders. Unlike most PPI drugs, rabeprazole is spontaneously reduced to rabeprazole sulfide (thioether) when it is given to patients. As a result, rabeprazole sulfide is considered one of the active metabolites of rabeprazole. Rabeprazole sulfide is mainly metabolized to desmethyl rabeprazole sulfide by CYP2C19 and CYP2D6 in people. However, the pharmacological efficacy and safety of desmethyl rabeprazole sulfide have not yet been investigated. Its usage is challenging due to the high cost associated with the drug. In this study, we found CYP102A1 mutants that can produce desmethyl rabeprazole sulfide as a major metabolite of rabeprazole sulfide. The chemical characteristics of the major product were confirmed using high-performance liquid chromatography, LC-mass spectrometry, and nuclear magnetic resonance spectroscopy. CYP102A1 mutants R47L/F87V/L188Q, R47L/F87V/L188Q/A335V/Q359R, and R47L/F87V/L188Q/I254V/D351E showed kcat values of 39, 93, and 88 min-1, respectively, for O-desmethylation of rabeprazole sulfide. Furthermore, the highest concentration of desmethyl rabeprazole sulfide product from 2 mM rabeprazole sulfide at optimal conditions was obtained in bacterial whole-cell biotransformation with the R47L/F87V/L188Q mutant, reaching 0.63 mM at 4-h incubation. In conclusion, we present a platform that facilitates the efficient and sustainable production of the desmethylated product from rabeprazole sulfide for use in the biopharmaceutical industry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biological Sciences and Technology, Chonnam National University, 77 Yongbongro, Gwangju 61186, Republic of Korea.
- Namhae Garlic Research Institute, 2465-8 Namhaedaero, Gyeongsangnamdo 52430, Republic of Korea.
- School of Biological Sciences and Biotechnology, Graduate School, Chonnam National University, 77 Yongbongro, Gwangju 61186, Republic of Korea.
- School of Biological Sciences and Technology, Chonnam National University, 77 Yongbongro, Gwangju 61186, Republic of Korea. Electronic address: chyun@chonnam.ac.kr.
- School of Biological Sciences and Technology, Chonnam National University, 77 Yongbongro, Gwangju 61186, Republic of Korea. Electronic address: nguyenanh@chonnam.ac.kr.
Förderung
- National Research Foundation of Korea
- Ministry of Science, ICT and Future Planning
Zitieren
APA
Cao, N. T., Cha, G. S., Kim, J. H., Lee, Y., Yun, C. H., & Nguyen, N. A. (2023). Production of an O-desmethylated product, a major human metabolite, of rabeprazole sulfide by bacterial P450 enzymes. Enzyme and Microbial Technology. https://doi.org/10.1016/j.enzmictec.2023.110328
Vancouver
Cao NT, Cha GS, Kim JH, Lee Y, Yun CH, Nguyen NA. Production of an O-desmethylated product, a major human metabolite, of rabeprazole sulfide by bacterial P450 enzymes. Enzyme and Microbial Technology. 2023. doi:10.1016/j.enzmictec.2023.110328
BibTeX
@article{Cao2023,
author = {Cao, Ngoc Tan and Cha, Gun Su and Kim, Jeong-Hoon and Lee, Yujin and Yun, Chul-Ho and Nguyen, Ngoc Anh},
title = {Production of an O-desmethylated product, a major human metabolite, of rabeprazole sulfide by bacterial P450 enzymes},
journal = {Enzyme and Microbial Technology},
year = {2023},
doi = {10.1016/j.enzmictec.2023.110328}
}
EUVIMED